ELDN - CIK 0001404281
Eledon Pharmaceuticals, Inc. (ELDN) reported net income of -$45.62M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$45.62M | -26.1% |
| FY 2024 | -$36.18M | +69.0% |
| FY 2023 | -$116.54M | -32.5% |
| FY 2022 | -$87.97M | -154.9% |
| FY 2021 | -$34.51M | -51.3% |
| FY 2020 | -$22.81M | -42.5% |
| FY 2019 | -$16.01M | -13.8% |
| FY 2018 | -$14.06M | -7.2% |
| FY 2017 |
Eledon Pharmaceuticals, Inc. (ELDN) reported net income of -$45.62M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2012 and fiscal 2025, Eledon Pharmaceuticals, Inc.'s net income declined from -$9.65M to -$45.62M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| -$13.12M |
| -131.9% |
| FY 2016 | -$5.66M | +87.5% |
| FY 2015 | -$45.09M | -93.5% |
| FY 2014 | -$23.30M | -48.1% |
| FY 2013 | -$15.72M | -63.0% |
| FY 2012 | -$9.65M | - |